Physician profile
Nathan Stroble
NPI 1306354576
$2,560.53
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $104 · 2022: $897 · 2023: $889 · 2024: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,523 · Education: $36.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,523.47 |
| Education | $36.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $497.41 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $442.51 | 2022-2024 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Alkermes, INC. | $318.90 | 2022-2024 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $312.99 | 2021-2024 | Caplyta |
| Indivior INC. | $214.46 | 2022-2024 | Perseris |
| Teva Pharmaceuticals USA, INC. | $182.04 | 2023-2024 | Uzedy, Austedo Xr, Austedo |
| Lundbeck LLC | $140.78 | 2022-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $137.05 | 2022-2023 | Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $116.55 | 2022-2024 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $94.46 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $48.24 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.44 | 2022-2023 | Trintellix |
| Teleflex LLC | $22.70 | 2024 | Arrow |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Stroble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.